Multidisciplinary Study of Right Ventricular Dysplasia

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Frank Marcus, University of Arizona
ClinicalTrials.gov Identifier:
NCT00024505
First received: September 18, 2001
Last updated: January 15, 2013
Last verified: January 2013
  Purpose

The purpose of this study is to investigate the cardiac, clinical, and genetic aspects of arrhythmogenic right ventricular dysplasia (ARVD), a progressive disorder that predominantly affects the right side of the heart and causes ventricular arrhythmias.


Condition
Heart Diseases
Arrhythmogenic Right Ventricular Dysplasia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Multidisciplinary Study of Right Ventricular Dysplasia

Resource links provided by NLM:


Further study details as provided by University of Arizona:

Primary Outcome Measures:
  • Identifying the cardiac, clinical, and genetic aspects of ARVD [ Time Frame: Measured during the course of the study ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Blood


Enrollment: 320
Study Start Date: September 2001
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Detailed Description:

BACKGROUND:

ARVD is an uncommon disorder but is considered a major cause of sudden death and life-threatening arrhythmia, in particular in the young population. The prevalence of ARVD is unknown but is certainly underestimated because of the difficulties in obtaining a correct diagnosis. It appears to be particularly frequent in certain geographical areas, probably for a founder effect, such as in northeast Italy, where a large number of ARVD cases and families have been described. A noncontrolled study of the University of Padua reported a frequency of familial forms of about 30 percent, indicating the existence of a defective gene in a large proportion of cases. In the United States the frequency of the disease is unknown, but the number of cases seems to be increasing.

The etiology of ARVD was unknown until very recently. The main hypothesis involved apoptotic mechanisms and, in some cases, a viral infection. However, in the last couple of years, two genes causing ARVD have been identified. The first one encodes plakoglobin, a protein of the cardiac junctions with adhesive and signaling functions. The second ARVD gene is the cardiac ryanodine receptor (RYR2), which has been characterized only very recently by Dr. Danieli's group. In fact, this discovery is so recent that in this study, RYR2 is still considered a potential candidate. The discovery of the first disease genes provides the basis for a candidate gene approach following the hypothesis of a "final common pathway." Thus, major candidates become genes involved in cell-cell adhesion and encoding ion channels.

DESIGN NARRATIVE:

This is a multidisciplinary, multicenter, collaborative study investigating the cardiac, clinical, and genetic aspects of ARVD. The specific aims are (1) to establish a North American ARVD Registry enrolling ARVD patients and their family members, based on standardized diagnostic test criteria, in a prospective longitudinal follow-up study; (2) to determine the genetic background of ARVD by identifying chromosomal loci and specific gene mutations associated with this disorder; (3) to determine the influence of the genotype on the clinical course of patients with ARVD and explore phenotype-genotype associations that will contribute to improved diagnosis, risk stratification, and therapy; and (4) to develop quantitative methods to assess right ventricular function in order to enhance the specificity and sensitivity of ARVD diagnosis.

  Eligibility

Ages Eligible for Study:   12 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Referals to enrolling centers from communities

Criteria

Inclusion Criteria:

  • Males and females over the age of puberty
  • Suspected ARVD based on the presence of major or minor Task Force Criteria

Exclusion Criteria:

  • Children younger than 12 years of age
  • Internal cardioverter defibrillator (ICD) in place for more than 2 years (for probands)
  • Individuals with monomorphic ventricular ectopy of predominantly RBBB morphology
  • Individuals with obvious cardiomyopathic abnormalities of structure or function predominantly affecting the left ventricle
  • Individuals with other conditions that might be mistaken for right ventricular dysplasia such as congenital heart disease, e.g., atrial septal defect, anomalous drainage of the pulmonary vessels into the right atrium, and Ebstein's malformation
  • Individuals unwilling to undergo diagnostic testing at the nearest enrolling center
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00024505

Locations
United States, Arizona
University of Arizona
Tucson, Arizona, United States, 85724
Sponsors and Collaborators
University of Arizona
Investigators
Principal Investigator: Frank I. Marcus, MD University of Arizona
Principal Investigator: Jeffrey Towbin Baylor College of Medicine
Principal Investigator: Wojciech Zareba University of Rochester
  More Information

Additional Information:
Publications:
Piotrowicz K, Couderc JP, Towbin JA, Marcus F, Zareba W.. Repolarization dynamics and heart rate variability in patients with ARVD. Heart Rhythm 2005;2(1S)S223

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Frank Marcus, Professor Emeritus, University of Arizona
ClinicalTrials.gov Identifier: NCT00024505     History of Changes
Other Study ID Numbers: 983, U01HL065594-05, U01 HL65594, U01 HL65652, U01 HL65691
Study First Received: September 18, 2001
Last Updated: January 15, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Heart Diseases
Arrhythmogenic Right Ventricular Dysplasia
Cardiovascular Diseases
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiomyopathies
Congenital Abnormalities

ClinicalTrials.gov processed this record on July 24, 2014